Lynn Sage Breast Cancer Symposium | Conference

Progress Emerging With Optimal Adjuvant Therapy in Young Women With Breast Cancer

October 14th 2018

Determining the optimal adjuvant therapy in young women with breast cancer remains challenging, but some clarity is beginning to emerge.

Dr. Ruddy on the Importance of Genetic Testing in Breast Cancer

October 13th 2018

Kathryn Ruddy, MD, discusses how genetic testing could impact treatment of patients with breast cancer.

Challenges Remain in Treating Patients With Phyllodes Breast Tumors

October 13th 2018

Andrea V. Barrio, MD, discusses the challenges with phyllodes tumors of the breast and how to manage this disease moving forward.

Dr. Mittendorf Discusses Rationale for Updating the AJCC Staging System

October 13th 2018

Elizabeth Mittendorf, MD, PhD, discusses the rationale for updating the AJCC staging system in patients with breast cancer. This system was originally developed in the 1970s but is still used today.

Conventional View May Not Apply for All Triple-Negative Breast Cancers

October 13th 2018

All triple-negative breast cancers are not created equal, and clinicians should consider their inherent heterogeneity during diagnosis and treatment planning.

Expert Highlights Management of Locoregional Recurrence in Breast Cancer

October 13th 2018

Monica Morrow, MD, addresses how she treats patients with breast cancer who have locoregional recurrence and how therapeutic approaches have evolved over recent years.

Dr. McLaughlin on Lymphedema in Breast Cancer

October 12th 2018

Sara McLaughlin, MD, professor of Surgery, Mayo Clinic, discusses the frequency that lymphedema appears in patients with breast cancer and addresses the complications in identifying this after her presentation at the Lynn Sage Breast Cancer Symposium.

Emerging Role of TILs in Breast Cancer Leads to Expanding Pathology Practices

October 12th 2018

Just as immunotherapies are transforming clinical practice for oncologists, these new therapies are also changing the practice of pathology and offering new ways for oncologists and pathologists to collaborate and improve patient care.

Dr. Blanco on the Role of Pathology in Treatment of Breast Cancer

October 12th 2018

Luis Z. Blanco Jr., MD, assistant professor of Pathology, Northwestern University, discusses the role a pathologist plays in the treatment of a patient with breast cancer during a presentation at the Lynn Sage Breast Cancer Symposium.

Expanded FDA Clearances Speed Scalp Cooling Acceptance in Oncology Community

October 12th 2018

Scalp cooling to limit alopecia in patients with cancer who are receiving chemotherapy is edging closer to becoming a widespread patient offering following recent FDA clearances.

Molecular Testing, Immunotherapy To Be Highlighted at 20th Annual Breast Cancer Conference

September 29th 2018

Advances in subtype-specific treatments, immunotherapy, ongoing issues with younger patients, the optimal use of neoadjuvant and adjuvant regimens, and molecular testing will be discussed at the 20th Annual Lynn Sage Breast Cancer Symposium.

Dr. Cristofanilli on Endocrine Therapy for Breast Cancer

September 17th 2017

Massimo Cristofanilli, MD, professor of medicine, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, discusses endocrine therapy for patients with breast cancer.

Dr. Hurria on Challenges Facing the Geriatric Population with Breast Cancer

September 17th 2017

Arti Hurria, MD, director, Cancer and Aging Research Program, co-leader, Cancer Control and Population Sciences Program, professor, Department of Medical Oncology and Therapeutics Research and Department of Population Sciences, City of Hope, discusses challenges facing geriatric patients with breast cancer.

Biomarkers Needed for Premenopausal Women With Breast Cancer

September 17th 2017

Ongoing studies are hoping to find a biomarker to guide which premenopausal women with ER-positive breast cancer need extended adjuvant therapy and which need ovarian function suppression.

Older Breast Cancer Patients Require Special Consideration

September 17th 2017

Treating older patients with breast cancer must include more quality of life considerations and different types of survival calculations.

Stage, ER Status Guide HER2 Therapy Selection in Breast Cancer

September 17th 2017

The sequencing of therapies for patients with HER2-positive breast cancer is largely driven by stage of disease and hormone receptor status.

Implementation Research Key to Solving Global Cancer Care Puzzle

September 16th 2017

Health investment is failing to match the challenge presented by a growing cancer burden in countries at all economic levels, enhancing the need for new approaches that help optimize the delivery of care.

Precision Medicine Moving Beyond HER2 in Breast Cancer

September 16th 2017

There is a significant transformation underway in the treatment of breast cancer as research advances and new laboratory techniques continue to shrink the so-called "undruggable genome."

Dr. Muss on Adjuvant Therapy for Elder Patients with Breast Cancer

September 16th 2017

Hyman B. Muss, MD, School of Medicine, University of North Carolina (UNC)-Chapel Hill, Breast Cancer, Geriatric Oncology Program, Mary Jones Hudson Distinguished Professorship in Geriatric Oncology, UNC Lineberger Comprehensive Cancer Center, UNC School of Medicine, 2017 Giant of Cancer Care in Supportive/Palliative/Geriatric Care, discusses adjuvant therapy for elderly patients with HER2-positive or triple-negative breast cancer (TNBC).

Ovarian Suppression Individualization Warranted in Breast Cancer

September 16th 2017

Patients have a hard time with artificially induced menopause and some research suggests it may have a negligible effect on the success of their treatment.